Study wrapper · #941
Medical Management of Obesity: A Comprehensive Review of FDA-Approved and Investigational Therapies.
Raza SS, Zakir Z, Hashmat A, et al. Cureus. 2025.
DOI: 10.7759/cureus.96739PubMed: 41393574
Editor's note
This review surveys the obesity pharmacotherapy landscape, covering approved agents alongside investigational ones such as retatrutide. It summarizes efficacy, safety concerns, and patient-selection considerations without presenting new data. A reasonable orientation piece for readers new to the class.
Plain-language abstract
A narrative review of approved and investigational obesity medications, describing how semaglutide and tirzepatide have reshaped expectations and how retatrutide shows greater efficacy in early studies.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026